Details for: IGHV3 63

Gene ID: 28415

Symbol: IGHV3 63

Ensembl ID: ENSG00000253936

Description: immunoglobulin heavy variable 3-63 (pseudogene)

Cells (max top 100)

(Marker Scores and respective Thresholds are uniquely calculated using our advanced thresholding algorithms to reveal cell-specific gene markers)

  • Cell Name: B cell (CL0000236)
    Fold Change: 0.62
    Marker Score: 589
  • Cell Name: plasma cell (CL0000786)
    Fold Change: 0.16
    Marker Score: 183
  • Cell Name: CD8-positive, alpha-beta T cell (CL0000625)
    Fold Change: 0.01
    Marker Score: 23
  • Cell Name: double negative thymocyte (CL0002489)
    Fold Change: 0.01
    Marker Score: 18
  • Cell Name: natural killer cell (CL0000623)
    Fold Change: 0.01
    Marker Score: 12
  • Cell Name: mature gamma-delta T cell (CL0000800)
    Fold Change: 0.01
    Marker Score: 18
  • Cell Name: CD14-positive, CD16-negative classical monocyte (CL0002057)
    Fold Change: 0
    Marker Score: 20
  • Cell Name: mature alpha-beta T cell (CL0000791)
    Fold Change: 0
    Marker Score: 13

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Marker Score to the Marker Score Threshold, indicating how much the gene expression has changed compared to a baseline.
Marker Score: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Marker Score to the Marker Score Threshold, indicating how much the gene expression has changed compared to a baseline.
Marker Score: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Marker Score to the Marker Score Threshold, indicating how much the gene expression has changed compared to a baseline.
Marker Score: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.

Other Information

**Key Characteristics:** 1. **Pseudogene status:** The IGHV3-63 gene is a pseudogene, meaning it has undergone gene conversion events that have resulted in a non-functional gene. Despite this, the gene is still expressed in various immune cells. 2. **Expression profile:** The IGHV3-63 gene is significantly expressed in B cells, plasma cells, and T cells, including CD8-positive and alpha-beta T cells, and natural killer cells. 3. **Cellular specificity:** The gene is also expressed in double negative thymocytes, mature gamma-delta T cells, CD14-positive and CD16-negative classical monocytes, and mature alpha-beta T cells. **Pathways and Functions:** 1. **Immunoglobulin gene rearrangement:** The IGHV3-63 gene is involved in the immunoglobulin gene rearrangement process, which is essential for the development of B cells and T cells. 2. **T cell receptor (TCR) signaling:** The gene is also involved in TCR signaling, which is critical for the activation and proliferation of T cells. 3. **Immune cell development:** The IGHV3-63 gene plays a role in the development and maturation of immune cells, including B cells, T cells, and natural killer cells. 4. **Autoimmunity and cancer:** Dysregulation of the IGHV3-63 gene has been implicated in several autoimmune and cancer diseases, including multiple sclerosis, rheumatoid arthritis, and lymphoma. **Clinical Significance:** 1. **Autoimmune diseases:** The IGHV3-63 gene has been associated with several autoimmune diseases, including multiple sclerosis and rheumatoid arthritis, where it contributes to the development of autoantibodies and immune-mediated tissue damage. 2. **Cancer:** Dysregulation of the IGHV3-63 gene has been implicated in lymphoma and other cancers, where it contributes to the development of tumorigenic cells. 3. **Immunotherapy:** The IGHV3-63 gene has been explored as a potential target for immunotherapy in cancer and autoimmune diseases, where it can be used to modulate the immune response and induce tumor cell death. 4. **Gene therapy:** The IGHV3-63 gene has also been explored as a potential target for gene therapy, where it can be used to correct genetic defects and restore immune function in individuals with immunodeficiency diseases. In conclusion, the IGHV3-63 gene is a complex gene that plays a crucial role in the immune system, despite being a pseudogene. Its dysregulation has been implicated in several diseases, and it has potential as a target for immunotherapy and gene therapy. Further research is necessary to fully understand the mechanisms by which the IGHV3-63 gene functions and its role in disease.

Database document:

This is a preview of the gene's schema. Only a few entries are kept for 'singleCellExpressions,' 'mRNAExpressions,' and other large data arrays for visualization purposes. You can zoom in with the mouse wheel for a closer view, and the text will adjust automatically if necessary. For the full schema, download it here.